This document provides methods and materials related to assessing responsiveness to lenalidomide, thalidomide, and/or other IMiDs (structural and functional analogues of thalidomide that represent a promising new class of immunomodulators). For example, methods and materials for using CRBN levels to determine whether or not cancer cells (e.g., multiple myeloma cells) are susceptible to lenalidomide, thalidomide, and/or other IMiDs are provided.

This document provides methods and materials related to assessing responsiveness to lenalidomide thalidomide and/or other IMiDs (structural and functional analogues of thalidomide that represent a promising new class of immunomodulators). For example methods and materials for using CRBN levels to determine whether or not cancer cells (e.g. multiple myeloma cells) are susceptible to lenalidomide thalidomide and/or other IMiDs are provided.

This document provides methods and materials related to assessing responsiveness to lenalidomide thalidomide and/or other IMiDs (structural and functional analogues of thalidomide that represent a promising new class of immunomodulators). For example methods and materials for using CRBN levels to determine whether or not cancer cells (e.g. multiple myeloma cells) are susceptible to lenalidomide thalidomide and/or other IMiDs are provided.

PROBLEM TO BE SOLVED: To provide a medicament useful for ameliorating psychiatric symptoms or mental dysfunctions in patients suffering from schizophrenia or psychosis similar thereto. SOLUTION: Thalidomide or lenalidomide which is a derivative thereof is used as a pomalidomide therapeutic agent for the schizophrenia. COPYRIGHT: (C)2010JPO&INPIT

Methods and pharmaceutical compositions for regulations of Guanosine- (G-) and/or Guanosine-cytosine-rich (GC-rich) nucleic acid expressions are provided. The methods include a step of interacting the G- and/or GC-rich region of the nucleic acid with thalidomide and the pharmaceutical compositions include the thalidomide and a pharmaceutical carrier.

Provided are 4'-arylmethoxy isoindoline compounds and pharmaceutically acceptable salts solvates clathrates stereoisomers and prodrugs thereof. Methods of use and pharmaceutical compositions of these compounds are disclosed. The compounds are derivatives of hydroxy thalidomide active against cancer.

Provided are 4'-arylmethoxy isoindoline compounds and pharmaceutically acceptable salts solvates clathrates stereoisomers and prodrugs thereof. Methods of use and pharmaceutical compositions of these compounds are disclosed. The compounds are derivatives of hydroxy thalidomide active against cancer.